RE:RE:RE:RE:pp for 3000 test a dayPPs are never popular and particularly two so close together as it is dilution at its finest and it DOES impact sp health as we own less and less of each share. However, I believe something like $4.9 mill is earmarked for the commercialization of Aristotle and that is pretty much the second PP. Colon sentry had no such marketing campaign and was unsuccessful - I believe they have learned that it takes money for a successful launch - this is now a different company - WHY - because after 15 years Aristotle is finally a few months away from roll out and the company is currently making money like never before thru Covid - unprecedented times really for this enterprise.
The recent hirings are proof that we are increasing testing so that is not a concern - $18-30 million projected earning is nothing to sneeze at either for a .08 cent pre RS company.